Perrigo completes sale of Tysabri drug royalty to RPI for $2.85bn
Drug manufacturer Perrigo has completed the sale of its right to the royalty stream from the global net sales of the drug Tysabri (natalizumab) to Royalty Pharma's (RPI) affiliate RPI Finance Trust for $2.85bn.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Pharmaceuticals | Tysabri